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Abstract
Background—Previous reports have suggested that levels of advanced glycation end product-
modified LDL (AGE-LDL) increase in patients with diabetes due to elevated plasma glucose.
However, understanding of the mechanisms by which AGE-LDL may accelerate atherogenesis
remains incomplete.
Methods and Results—Microarray and reverse transcription real-time PCR (RT-PCR) analyses
revealed that AGE-LDL significantly increased levels of CC chemokine receptor 2 (CCR2) mRNA
in human macrophages compared with LDL, an effect accompanied by increased levels of CCR2
protein. Flow cytometry also showed that AGE-LDL increases CCR2 expression on the cell surface
following stimulation (48 hours) (P<0.05). This effect appeared to depend on the receptor for AGE
(RAGE), since an anti-RAGE antibody significantly blocked increased CCR2 mRNA. Functional
studies demonstrated that exposure of THP-1 monocytoid cells to AGE-LDL increases chemotaxis
mediated by monocyte chemoattractant protein-1 (MCP-1) up to 3-fold compared to LDL treatment
(P<0.05).
Conclusions—These data show that AGE-LDL can increase CCR2 expression in macrophages
and stimulate the chemotactic response elicited by MCP-1. This novel mechanism may contribute
to accelerated atherogenesis in diabetic patients.
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Diabetes mellitus (DM) associates with increased incidence of macrovascular complications
including coronary artery and peripheral vascular diseases [1-3]. Although the mechanisms for
DM acceleration of atherosclerosis remain incompletely understood, the persistence of high
plasma glucose levels in DM patients creates favorable conditions for non-enzymatic glycation
of proteins and lipids and formation of advanced glycation end-products (AGE) [4]. AGE may
promote vascular dysfunction in diabetes by various mechanisms including activation of the
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endothelium, thus resulting in increased monocyte chemoattractant protein-1 (MCP-1)
expression [5] and induction of smooth muscle proliferation [6].
The non-enzymatic glycation of LDL can occur in vivo when blood glucose chemically
modifies lysine residues of LDL apolipoprotein-B [7]. The plasma levels of AGE-modified
LDL (AGE-LDL) increase in DM patients due to elevated concentrations of plasma glucose
[7-9]. In vitro studies demonstrated that AGE-LDL from diabetic subjects adversely affects
cultured cells relevant to atherosclerosis, resulting in cholesteryl ester accumulation in
monocyte-derived macrophages and procoagulant effects on endothelial cells [9,10]. Indeed,
LDL glycation and oxidation [11,12], alone or in combination, may contribute to the increased
atherogenic risk in DM patients [13]. The toxicity of AGE-LDL [14] and its role in the
pathogenesis of atherosclerosis may relate to its prolonged presence in the circulation [15],
which results from impaired cellular uptake [16,17].
Vascular inflammation plays a central role in atherogenesis [18,19]. Chemokines regulate
leukocyte migration and infiltration into the vascular wall, a critical initial step in lesion
formation [19-21]. MCP-1, a monocyte/macrophage chemoattractant that contributes to the
pathogenesis of chronic inflammation, belongs to the CC subfamily of chemokines [22]. The
effects of MCP-1 depend primarily on CC chemokine receptor 2 (CCR2) [22]. Targeted
inactivation of either the MCP-1 or the CCR2 gene markedly decreased lesion formation in
apoE-deficient mice [23], indicating that CCR2 engagement contributes to the development
of atherosclerotic lesions. In particular, atheromata from diabetic patients have accentuated
accumulation of macrophages, although the mechanisms remain unknown [24,25]. This study
demonstrates that AGE-LDL increases CCR2 expression in human macrophages and
stimulates MCP-1-mediated THP-1 monocytoid cell chemotaxis. These results contribute to
the understanding of AGE-LDL-mediated mechanisms that may promote macrophage
accumulation and atherosclerosis in diabetic patients.
Methods
Preparation of AGE-LDL
LDL (d= 1.019 to 1.063 g/ml) was separated from normal human plasma, dialyzed extensively
at 4°C in the dark, and modified in vitro by glycation as described previously [17]. Briefly, we
incubated LDL at 37°C for 7 days under argon gas in the presence of 25 mmol/L glucose, and
then removed unincorporated sugars by repeated and extensive dialysis. We incubated control
LDL under similar conditions, but without glucose. We passed the LDL preparations through
sterile filters (0.22 μm) and stored them in the dark under argon gas at 4°C. Endotoxin was
<40pg endotoxin/ml as determined by the chromogenic Limulus amoebocyte assay (Cape Cod,
Falmouth, MA). Protein modification was evaluated by measuring pentosidine formation
spectrofluorometrically (excitation at 335 nm, emission at 385 nm) [26]. Oxidation was
measured using a highly sensitive sandwich ELISA using DH3, a monoclonal antibody that
recognizes oxidatively modified lipoproteins (Kyowa Medex, Tokyo, Japan), and an anti-
human apoprotein B monoclonal antibody (BD Biosciences) [27]. In the ELISA plate, various
concentrations of standard oxidized LDL, which was prepared by incubating LDL with 5
μmol/L CuSO4 at 37°C for 3 hours, were run simultaneously to determine a standard curve.
The concentrations of oxidized LDL are expressed in ng/5μg LDL protein.
Macrophage isolation and culture
We isolated monocytes by density gradient centrifugation that employed Lymphocyte
Separation Medium (ICN Biomedicals, Aurora, OH) and subsequent adherence to cell culture
dishes from leukopacs of healthy donors. Monocytes were cultured for 10 days in RPMI 1640
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containing 5% human serum (Atlanta Biologicals, Lawrenceville, GA) to obtain macrophages
[28]. THP-1 cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum.
Microarray analysis
Macrophages were deprived of serum in RPMI 1640 medium for 12 hours and then stimulated
by adding fresh medium containing either 100μg/mL AGE-LDL or 100μg/mL LDL. Total
RNA was isolated with an RNeasy Mini Kit (Qiagen) and tested for quality on agarose gels.
We used total RNA (10μg) for microarray analysis on Affymetrix hg U133 Plus 2.0 chips
(Affymetrix). The arrays were scanned and the data were captured using the Affymetrix
GeneChip Laboratory Information Management System. Criteria for differential regulation by
AGE-LDL treatment were set as >2.0-fold increase or decrease at a probability value of <0.05
(n=3).
Reverse transcription-quantitative PCR
Total RNA from human macrophages (5μg) was reverse transcribed by Superscript II
(Invitrogen) following the manufacturer's instructions. Quantitative PCR was performed in a
MyiQ Single-Color Real-Time PCR system (Bio-Rad, Hercules, CA) (primer sequences given
in Table 1). The levels of the different mRNAs were normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA levels and presented as fold-difference of AGE-LDL- treated
cells vs. LDL-treated cells. An anti-human Receptor for AGE (RAGE) mouse monoclonal
antibody and its IgG2b isotype control (R&D systems) served to test the involvement of RAGE
by blocking receptor-ligand interactions.
Western blot analysis
Cell extracts (20-30 μg total protein/lane) were separated by standard SDS-PAGE under
reducing conditions and blotted to polyvinylidene difluoride membranes (PerkinElmer Life
Sciences, Boston, MA). The blots were blocked with 5% defatted dry milk in Tris-buffered
saline (TBS)/0.05% Tween 20, and incubated overnight with primary antibodies (1:1,000) in
blocking buffer. After washing the membranes three times with TBS/0.05% Tween 20, we
incubated them with peroxidase-conjugated goat anti-mouse or goat anti-rabbit antibodies
(Jackson Immunoresearch) for 1h, washed them again, and developed them with a
chemiluminiscence reagent (Perkin Elmer Life Sciences). We used the following primary
antibodies: anti-CCR2 from Santa Cruz, anti-human GAPDH from Biodesign, and anti-AGE
from ICN. We conducted densitometric analysis using the National Institutes of Health Image
J processing system.
Analysis of cell surface CCR2
We washed adherent monocyte-derived cells X 2 with sterile PBS and added 5mL 5 mM
EDTA/PBS per 100mm dish and incubated at 37°C for 5 minutes. We gently pipetted the cells
off the dish and collected them without scraping. This method did not injure macrophages as
determined by trypan blue exclusion and phase contrast micrographic inspection. The amount
of CCR2 protein on the cell surface was estimated by flow cytometry as described [29]. CCR2
surface expression was expressed as specific mean fluorescence intensity (MFI), obtained by
subtracting the MFI of control cells from that of cells labeled with anti-CCR2 antibody.
Chemotaxis assay
The chemotactic activity of THP-1 monocytoid cells in response to 2 nmol/L MCP-1 was
measured in a 96-well 5mm Cell Migration Plate Assembly (Chemicon) as described elsewhere
[30]. The result was expressed as the number of cells migrating in response to MCP-1.
Isoda et al. Page 3
Atherosclerosis. Author manuscript; available in PMC 2009 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Statistical analysis
Results are mean ± SEM. Differences between groups were determined using ANOVA with
Bonferroni post hoc test. Two groups were compared using Student's t test. A value of p<0.05
was regarded as a significant difference.
Results
AGE-LDL increases CCR2 mRNA expression in human macrophages
To test the hypothesis that AGE-LDL elicits programs of cell activation involved in
atherogenesis, we prepared AGE-LDL by incubating LDL with glucose at 37°C for 7 days.
Longer incubation times caused detectable apoB100 fragmentation (not shown). Seven days
of incubation yielded a significant increase in the formation of pentosidine (Fig.1a), a marker
of protein modification [26]. The apoB100 moiety of AGE-LDL remained unfragmented (Fig.
1B, right panel) but reacted with an anti-AGE antibody that did not recognize native LDL (Fig.
1B, left panel). To evaluate the possibility of oxidation, we also measured oxidized LDL levels
using a highly sensitive sandwich ELISA method (Table 2). Oxidized LDL levels in AGE-
LDL were similar to those in control LDL incubated for 7 days under argon gas. In contrast,
levels of oxidized LDL in the LDL incubated for 7 days without argon gas were much higher
than in AGE-LDL or control LDL. These results show that argon gas prevented LDL oxidation
and indicate that the actions of glycated LDL on macrophages reported here do not likely result
from oxidative modification.
After treating human macrophages with AGE-LDL or LDL for 6h (100μg/ml), we isolated
total RNA and subjected it to DNA microarray analysis. AGE-LDL treatment increased CCR2
mRNA levels 3.23-fold compared with LDL treatment. RT-PCR analysis verified that AGE-
LDL increased the expression of CCR2 (Fig. 2a) and demonstrated that the effect depended
on RAGE, because it declined significantly after treatment of macrophages with an anti-RAGE
antibody (Fig. 2b) but not with isotype control IgG (data not shown).
AGE-LDL increases CCR2 protein and cell surface expression
Levels of CCR2 increased markedly (∼ 3-fold) in macrophages following AGE-LDL treatment
(48 hours), as determined by Western blotting (Fig. 3a) and densitometry (Fig. 3b). AGE-LDL
induced augmented expression of cell surface CCR2 (5-fold), as revealed by flow cytometry
(Fig. 4).
AGE-LDL increased MCP-1-mediated chemotaxis of THP-1 monocytes
Similarly to its effect in monocyte-derived macrophages, AGE-LDL augmented the expression
of CCR2 in THP-1 monocytoid cells (not shown). Therefore, to examine the functional
implications of AGE-LDL-induced CCR2 expression, further experiments determined the
chemotactic response of THP-1 monocytoid cells to MCP-1, a specific CCR2 ligand. AGE-
LDL treatment increased the chemotactic activity of THP-1 monocytoid cells 2.6-fold
compared to LDL-treated cells (Fig. 5).
Discussion
AGE-LDL accumulates in diabetic patients [7-9], but pathophysiological effects of AGE-LDL
remain incompletely characterized. AGE-LDL can stimulate the proliferation and
differentiation of vascular smooth muscle cells [31] and also increase MCP-1 expression in
endothelial cells [32], potentially promoting monocyte recruitment [22]. The present study
demonstrates that AGE-LDL also increases expression of the MCP-1 receptor CCR2 in
macrophages and promotes chemotaxis of monocytes directed by MCP-1. Our results
underscore the effect of AGE-LDL on different cell types involved in atherosclerosis.
Isoda et al. Page 4
Atherosclerosis. Author manuscript; available in PMC 2009 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Since an anti-RAGE antibody can suppress this cellular response to AGE-LDL, the present
results demonstrate that RAGE participates in AGE-LDL-induced CCR2 expression. Because
RAGE expression increases in infiltrating macrophages in the vasculature of diabetic subjects,
this finding may have particular disease relevance [33]. Importantly, the anti-RAGE IgG
concentration (50 μg/mL) in our antibody blocking experiments completely suppressed AGE-
BSA-induced gene expression [34], but only inhibited AGE-LDL-induced CCR2 expression
by 60-70% (Fig. 2b), suggesting that other receptors or AGE-binding proteins, e.g., scavenger
receptors type I and type II, oligosaccharide transferase-48 (AGE-R1), 80K-H phosphoprotein
(AGE-R2), and galectin-3 (AGE-R3), may also participate in CCR2 regulation by AGE-LDL
[35].
In apoE-deficient mice ingesting a high-fat diet, deletion of CCR2, the only established
functional receptor for MCP-1 on hematopoietic cells, afforded significant protection against
macrophage accumulation and atherosclerotic lesion formation [23]. Similar studies in mice
fed a regular chow diet showed that CCR2-deficient mice resisted development of
atherosclerosis better than wild-type mice [36]. Such studies provide strong evidence that
activation of CCR2, presumably by MCP-1, contributes to foam cell formation, one of the
earliest manifestations of atherosclerosis. Thus, excessive recruitment of monocytes into the
arterial intima resulting from enhanced MCP-1-mediated chemotaxis may provide a
mechanism for concerted action of high serum AGE-LDL levels with LDL and other AGEs
that promotes atherosclerosis in DM patients.
We used argon gas to prevent the oxidation of AGE-LDL and control LDL during the
preparation, and verified the inhibition of oxidation by sandwich ELISA assay. Our preliminary
data showed that oxidized LDL reduced MCP-1-mediated chemotaxis compared with LDL, a
result compatible with previous reports showing that oxidized LDL caused a rapid reduction
of CCR2 expression in monocytes, rendering these cells non-responsive to MCP-1 [25,37].
Our findings suggest differing cellular responses to AGE-LDL and oxidized LDL. Oxidized
LDL, found mainly in atherosclerotic lesions, may block emigration from the intima and retain
monocytes at sites of inflammation, and hence promote intimal macrophage accumulation. In
conclusion, AGE-LDL augments both mRNA and protein levels of CCR2 and increases
MCP-1-mediated chemotaxis. As atheromata in patients with DM have accentuated
accumulation of mononuclear phagocytes as well as RAGE, our findings suggest a new
mechanism by which AGE-LDL can promote atherogenesis in DM patients.
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Figure 1.
Characterization of AGE-LDL. LDL was incubated with or without glucose as described in
the Methods section and: A) pentosidine formation was detected by fluorescence at 335/385
nm; B) Samples were electrophoresed through SDS-polyacrylamide gels and stained with
Coomasie blue (right panel) or analyzed by Western blot using an anti-AGE antibody (left
panel).
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Figure 2.
AGE-LDL increased CCR2 mRNA level in human macrophages. A) The CCR2 mRNA level
was quantified by RT-PCR following 6 hours of treatment of macrophages with either LDL
or AGE-LDL. B) Cells were preincubated with 50 μg/mL of either anti-RAGE or isotype
control antibodies for 1h before stimulation. Data are normalized to the respective expression
levels in LDL-treated cells, and shown as mean ± SEM; n=6. The experiments were performed
three times for each donor.
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Figure 3.
AGE-LDL increased CCR2 protein levels in human macrophages. A) Macrophages were
treated with either LDL or AGE-LDL for 24 or 48 hours. Western blot analyses were performed
to detect CCR2 (upper), using GAPDH (lower) as a loading control. Similar results were
observed in cells from two additional donors. The experiments were done three times for each
donor. B) Densitometric analysis of the immunoblots in A). The intensity of the bands
corresponding to CCR2 was normalized to the intensity of GAPDH and expressed as mean ±
SEM (n = 3).
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Figure 4.
AGE-LDL increased cell surface expression of CCR2. Macrophages were incubated in the
presence of either LDL or AGE-LDL for 48 hours, and CCR2 surface expression was
determined by flow cytometry with anti-CCR2 IgG and expressed as specific mean
fluorescence intensity (MFI). Data are shown as mean ± SEM (n=3). The experiments were
done twice for each donor.
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Figure 5.
AGE-LDL stimulated MCP-1-mediated THP-1 cell chemotaxis.
THP-1 monocytoid cells were incubated with either AGE-LDL or LDL for 48 hours before
chemotaxis determination. Data are shown as mean ± SEM (n=3). The experiments were done
twice for each donor.
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Table 1
PCR primers
Forward Reverse
CCR2 TCCATTCTCTCAGGCTTGC TGAGCATCAAGGACATCTG
GAPDH TGAAGGTCGGAGTCAACGGATTTGGTCGTA ATCTCGCTCCTGGAAGATGGTGATGGGATT
CC chemokine receptor 2 (CCR2); glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
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Table 2
The levels of oxidized LDL
Fresh LDL LDL AGE-LDL LDL without argon
0.69 0.75 0.79 1.56
The concentrations of oxidized LDL are expressed in ng/5μg LDL protein.
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